Intellectual impairment is a well-established concomitant of Parkinson's disease, -3 although the precise physiopathological basis of the deficits remains poorly understood.4 The possibility that deficient dopaminergic transmission in the central nervous system is responsible for some of these cognitive disorders has been postulated on the basis of the following evidence: improved performance on neuropsychological tests has been observed after levodopa treatment,5 -7 or during "on" periods in patients with on-off fluctuations;8 significant correlations were found between various neuropsychological dis- 
Intellectual impairment is a well-established concomitant of Parkinson's disease, -3 although the precise physiopathological basis of the deficits remains poorly understood. 4 The possibility that deficient dopaminergic transmission in the central nervous system is responsible for some of these cognitive disorders has been postulated on the basis of the following evidence: improved performance on neuropsychological tests has been observed after levodopa treatment,5 -7 or during "on" periods in patients with on-off fluctuations;8 significant correlations were found between various neuropsychological disturbances and Parkinsonian motor disability' 9 resulting from central dopaminergic lesions;'0 similar cognitive disturbances have been demonstrated in MPTP-induced Parkinsonism,"l a well documented model of selective destruction of dopaminergic neurones in the substantia nigra. 2 13 The dopaminergic hypothesis of cognitive dysfunction in Parkinson's disease'4 is, however, still controversial. The beneficial effect of levodopa on cognitive functions has been observed only at early stages of the disease, 15 and is more likely the reflection of a general increase in altertness, the so-called awakening effect, '6 17 or changes in affective state,7 18 than an improvement in specific cognitive operations.
Furthermore, Rafal and his collaborators '9 were unable to detect an amelioration of cognitive function in Parkinsonian patients after levodopa treatment Patients and methods
A-Patients
After exclusion of patients with severe disability who could not be taken off therapy, and those with severe dysarthria, visual disorders, mental confusion, severe depression, or inability to cooperate, 120 in-patients with idiopathic Parkinson's disease were retained for the study (table 1). All were under treatment with levodopa (mean daily dose, 878 ± 33mg; mean duration of treatment, 5 2, SEM 04 years) plus a peripheral dopa-decarboxylase inhibitor. All other antiparkinsonian drugs were withdrawn. Levodopainduced abnormal involuntary movements were observed in 57 patients and severe fluctuations in performance in 49. B-Evaluation of motor performance Parkinsonian motor disability was evaluated after treatment was interrupted. The period of withdrawal varied from 18 hours in patients with severe on-off phenomena, to 6 days in the least affected subjects.21 Global motor disability (hereafter termed basal score) was assessed on a scale of 0-92 (modified Columbia scale).22 Akinesia, tremor and rigidity were each scored from 0 to 20, and gait disorder and dysarthria from 0 to 4. In order to permit comparison of patients with differing disease durations, the ratio of the basal motor score to the duration of the disease (hereafter termed rate of deterioration) was calculated for each subject. 23 Motor performance during levodopa treatment was evaluated 2 hours after the patients received their usual morning dose, I to 10 days after therapy was resumed: that is, when the effect of the drug was considered to be maximal and stable.2" The Parkinsonian score under treatment (hereafter called treated score) reflects residual motor symptoms unalleviated by levodopa and, presumably, therefore, is the result of non-dopaminergic lesions in the brain. The difference between the basal score and the treated score (hereafter called the levodopa responsive score) provides an index of levodopa-sensitive symptoms, thought to result from lesion of dopaminergic neurons. The rationale behind The correlations between the Parkinsonian motor scores and the neuropsychological tests are presented in tables 3 (global scores) and 4 (subtests of memory and frontal lobe function). Most of the neuropsychological scores were significantly and negatively correlated with the age of the patients at the onset of the Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? Wisconsin card sorting test, behavioural disorders), but none were correlated with tremor. Strong correlations were found between most of the neuropsychological test scores and the axial symptoms, gait disorder and dysarthria. None of the neuropsychological test scores were correlated with the levodoparesponsive motor score, but all were highly correlated with the residual motor score under levodopa treatment, the treated score.
In order to determine which of the characteristics of Parkinsonism (age at onset, duration of the disease, akinesia, rigidity, tremor, gait disorder, dysarthria) best predicted the neuropsychological test scores, stepwise multiple regression analyses were performed. The gait disorder score significantly predicted global efficiency (F = 15-7; p < 0 001), and scores on the linguistic function and gesture (F = 22; p < 0.001) and memory (F = 14-2; p < 0-001) tests. Dysarthria (F = 20-4; p < 0.001) and rigidity (F = 6-7; p < 0-05) significantly predicted impairment of frontal lobe function.
Stepwise multiple regression analyses were also performed to evaluate which of the items related to levodopa treatment (basal score, treated score, levodopa-responsive score; age at onset and duration of the disease) were the best predictors of neuropsychological performance. The treated score significantly predicted the impairment of global efficiency (F = 34 3; p < 0-001), the deterioration index (F = 25-6; p < 0.001), and scores on the verbal (F = 21-7; p < 0 001), PM-47 (F = 34-1; p < 0-001); linguistic and gesture (F = 53-7; p < 0 001); memory (F = 31-4; p < 0 001) and frontal lobe (F = 33 1; p < 0-001) tests. who reported that frontal lobe-like symptomatology predominates. The selection of subjects for inclusion in these studies, de novo Parkinsonians in the former,34 exclusion of patients with advanced global dementia in the latter,35 may explain the discrepancy with the present study on a less selected population which included demented patients representing the entire spectrum of the dementing process.36 This choice of patients was necessary, however, in order to explore the predictive value of clinical variables for the types of neuropsychological disorders observed in the patients. Most of the neuropsychological performances were negatively correlated with the age at onset of the disease, indicating that the incidence of intellectual deterioration was higher in patients who were older when the disease became manifest. This confirms several previous studies.37-3 However, when the scores of the neuropsychological tests were corrected for age (deterioration index, table 3), the correlations between age at onset and test performance were no longer significant. This raises the question as to whether the more severe cognitive impairment observed in lateonset Parkinsonism corresponds to a specific subtype of the disease, as suggested by Lieberman et al, 37 or whether it results from the consequences of aging, independent of the disease process.
There were only weak correlations between neuropsychological performance and disease duration, and no correlations at all between neuropsychological performance and the rate of motor deterioration, given by the ratio of the degree of motor disability (basal score) and the duration of the disease. The evolution of motor disability is, therefore, a poor predictor of the patients' intellectual status.
In agreement with earlier studies,' 36 37 40-42 significant correlations were found between all the neuropsychological test scores and the severity of motor impairment in patients withdrawn from levodopa (basal score, tables 3 and 4). From these correlations, it might be inferred that both cognitive and motor symptoms result from the same pathological changes in the brain. This conclusion does not hold, however, if the motor symptoms are segregated as a function of their response to levodopa. Rigidity and akinesia, both of which respond well to 50 The participation of other neuronal systems in the pathophysiology of intellectual deterioration in Parkinsonian patients cannot, however, be excluded. The significant correlations observed between the whole spectrum of cognitive deficits in Parkinsonian patients and the axial symptoms, dysarthria and gait impairment, suggest that the lesions responsible for the latters may also contribute to the former. If so, the nature and the location of the lesioned neurones remain to be determined. Finally, intellectual deterioration and axial symptomatology, strongly correlated in the present study, do not seem to result from dysfunction ofdopaminergic mechanisms. These symptoms, which do not respond to levodopa treatment, constitute a syndrome that becomes progressively more difficult to manage in the course of the disease.
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